← Back to patent-cliff list
rupatifen fumarate (Fujian Mindong Rejuvenation Pharmaceutical/Fujian Institute of Microbiology)
Tier C — Watch / traderupatifen fumarate (Fujian Mindong Rejuvenation Pharmaceutical/Fujian Institute of Microbiology)
-
Originator
-
First approval
-
Expiry (public)
No sales data
Peak sales
Small molecule
Type
Targets：Histamine receptor, PAFR
Indications (approved)：Seasonal allergic rhinitis, Allergic rhinitis, Hypersensitivity reaction
Regional status
US
-
EU
-
China
Phase III
2026-08-18
Japan
-
Synthetic routes & intermediates
Routes not yet onboarded — the daily pipeline enriches by priority (approved small molecules first); this page updates automatically.
Frequently asked questions
What are the approved indications of rupatifen fumarate (Fujian Mindong Rejuvenation Pharmaceutical/Fujian Institute of Microbiology)?
Approved indications include: Seasonal allergic rhinitis, Allergic rhinitis, Hypersensitivity reaction.
When does the rupatifen fumarate (Fujian Mindong Rejuvenation Pharmaceutical/Fujian Institute of Microbiology) patent expire?
No public expiry year is available for rupatifen fumarate (Fujian Mindong Rejuvenation Pharmaceutical/Fujian Institute of Microbiology) yet; this page updates once verified.
How do I get a quote for rupatifen fumarate (Fujian Mindong Rejuvenation Pharmaceutical/Fujian Institute of Microbiology) intermediates?
Open the CAS profile of the target intermediate from this page, or submit an RFQ directly — the CAS enters the matching flow automatically and the supply network responds with quotes.
Source: cross-verified data (structured fields only) · 2026-10-22